Black Pepper Piperine 95.

Curcumin is rapidly glucuronidated in the gut wall and liver, and piperine inhibits the UGT enzymes responsible, so more unconjugated curcumin reaches circulation. This is the textbook example of the interaction.

Standardised curcuminoid extracts face the same first-pass glucuronidation as plain curcumin, and piperine slows that step. Most curcuminoid products pair the two for exactly this reason.

Resveratrol is almost entirely converted to glucuronide and sulfate conjugates during first pass, and piperine inhibits those conjugating enzymes. The result is more of the parent molecule in circulation.

Piperine slows the intestinal glucuronidation of green tea catechins, raising how much unmetabolised EGCG survives the gut wall.

Quercetin is heavily sulfated and glucuronidated at the intestinal wall, and piperine inhibits those same enzymes. Less conjugation means more of the free flavonol reaching the bloodstream.

Piperine inhibits the P-glycoprotein pump that returns absorbed lipophilic molecules to the gut lumen, and CoQ10 is subject to that limit. Piperine is routinely included in CoQ10 formulas on this basis.

Piperine increases the absorption of fat-soluble carotenoids by slowing intestinal metabolism and increasing mucosal permeability. Beta carotene is one of the compounds where this has been characterised.

Berberine's very low oral exposure is driven largely by P-glycoprotein pumping it back into the gut lumen, and piperine inhibits that pump. Blocking the efflux route raises how much berberine is absorbed.

Whole green tea extract carries the same catechins that are conjugated at the intestinal wall, and piperine slows that conjugation. More of the intact catechin fraction therefore enters circulation.

Cell and animal work describes higher non-heme iron transfer across intestinal models in the presence of piperine, an absorption marker rather than a measured change in iron status in people. A randomised trial of curcumin co-formulated with piperine reported changes in iron-profile markers, but it tested the combination, not piperine alone. Regard the direction as plausible and the size as unquantified.

The trial gave curcumin co-formulated with piperine and measured serum 25-hydroxyvitamin D, a status marker. Because the comparison was formulation against placebo, the contribution of piperine specifically cannot be separated. It is a reason to consider the pairing, not evidence that piperine alone changes vitamin D status.

Carotenoids are absorbed after incorporation into bile-salt mixed micelles and are then handled by intestinal transporters and glucuronidation and oxidative metabolism. Piperine inhibits several of those metabolic steps. The reasoning is mechanistic and by analogy with other carotenoids, so it sits at early confidence for lutein specifically.

Piperine dissolves poorly in water and well in oil, so the presence of dietary or added lipid changes how much enters the mixed-micelle phase available for absorption. Medium-chain triglycerides also stimulate bile flow. This is formulation pharmacology rather than a trial result, which is why it sits below the established band.

Boswellic acids have low oral exposure and are substrates for efflux and phase II metabolism, the steps piperine inhibits. The pairing is widespread formulation practice; published human pharmacokinetic work on the specific combination is thin. Regard it as a formulation rationale rather than a measured lift.

The flavonolignans in silymarin reach the circulation mainly as conjugates because intestinal and hepatic glucuronidation is fast. Piperine slows that conjugation step in laboratory systems. The mechanism is coherent, human confirmation for this specific pair is limited.

Withanolides are lipophilic and subject to intestinal metabolism, and pepper has been used with botanical preparations in traditional practice for centuries. Modern pharmacokinetic data for this exact combination is sparse. Present it as a formulation and traditional pairing, not a measured effect.

Because caffeine is cleared almost entirely by hepatic CYP1A2, anything that slows that enzyme lengthens caffeine exposure. Piperine has broad P450 inhibitory activity in vitro, with the strongest human data on CYP3A4 substrates. Someone sensitive to stimulants should note the direction even though the magnitude for caffeine specifically is not established.

Oral melatonin has low and variable bioavailability precisely because first-pass CYP1A2 metabolism is extensive. Inhibiting that step would raise exposure. The evidence for piperine at this specific enzyme in people is limited, so this is a flag rather than a claim.

Animal work reports increased bile acid secretion and higher pancreatic lipase and amylase activity after piperine, alongside TRPV1 activation in the gut wall. Paired with supplemental digestive enzymes the intended direction is the same, more digestive capacity in the same window. The supporting data is preclinical.

Astaxanthin requires dietary fat and bile for micellar uptake, and its exposure is limited by that route and by efflux transport. Piperine acts on efflux and phase II metabolism. The inference is by analogy with beta-carotene work rather than direct measurement.

Adding piperine to a sulforaphane product is common in formulas but the metabolic logic differs, since sulforaphane is handled by glutathione S-transferase rather than by the P450 and glucuronidation steps piperine inhibits. The pairing should not be assumed to raise sulforaphane exposure. Naming that limit is more useful than implying a lift.